5.06
0.07 (1.40%)
| Penutupan Terdahulu | 4.99 |
| Buka | 5.04 |
| Jumlah Dagangan | 8,926 |
| Purata Dagangan (3B) | 28,596 |
| Modal Pasaran | 9,712,376 |
| Harga / Jualan (P/S) | 2.01 |
| Harga / Buku (P/B) | 0.330 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 Aug 2025 |
| Margin Operasi (TTM) | -991.41% |
| EPS Cair (TTM) | -33.20 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -76.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 52.79% |
| Nisbah Semasa (MRQ) | 3.13 |
| Aliran Tunai Operasi (OCF TTM) | -57.90 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -34.68 M |
| Pulangan Atas Aset (ROA TTM) | -34.57% |
| Pulangan Atas Ekuiti (ROE TTM) | -83.92% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Bolt Biotherapeutics, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.13 |
|
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.26% |
| % Dimiliki oleh Institusi | 46.17% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Nan Fung Group Holdings Ltd | 30 Sep 2025 | 58,347 |
| Board Of Trustees Of The Leland Stanford Junior University | 30 Sep 2025 | 35,978 |
| Julat 52 Minggu | ||
| Median | 7.00 (38.34%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Oct 2025 | 7.00 (38.34%) | Beli | 5.86 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Nov 2025 | Pengumuman | Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update |
| 01 Oct 2025 | Pengumuman | Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |